Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ciprofloxacin

FDA-approved product (injectable, injection), marketed as Cipro, Cipro In Dextrose 5% In Plastic Container, Cipro In Sodium Chloride 0.9% In Plastic Container and 8 more.

Registered studies
50+
Lab records
592
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ciprofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Cystitis
  • Eye infection
  • Gonorrhea
  • Infection
  • Otitis externa
  • Prostatitis
  • Pyelonephritis
  • Sinusitis
  • Typhoid fever
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones; Antiinfectives
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA02; WHO ATC S01AE03

Repurposing investigation

Ciprofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 118 of 130 lab records
  • E. coli: measured active in 134 of 137 lab records
  • K. pneumoniae: measured active in 264 of 294 lab records
  • M. tuberculosis: measured active in 29 of 31 lab records
Open Ciprofloxacin in ChEMBL Registered studies below
Show the latest 150 of 592 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ciprofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cefpodoxime vs Ciprofloxacin for Acute Cystitis

    NCT00194532 · start 2005-06

    Registered record
    Registry ID
    NCT00194532
    Conditions
    Urinary Tract Infection
    Interventions
    Cefpodoxime; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-06
    Completion
    2009-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection
    InterventionCefpodoxime; Ciprofloxacin
    PhaseNot applicable
    Registry statusCompleted

  • Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

    NCT00481689 · start 2004-05

    Registered record
    Registry ID
    NCT00481689
    Conditions
    Urinary Tract Infections
    Interventions
    Cipro XR (Ciprofloxacin, BAYQ3939)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-09
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCipro XR (Ciprofloxacin, BAYQ3939)
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

    NCT00004216 · start 1999-08

    Registered record
    Registry ID
    NCT00004216
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    salmonella VNP20009; cefixime; ceftriaxone sodium; ciprofloxacin; trimethoprim-sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1999-08
    Completion
    2008-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionsalmonella VNP20009; cefixime; ceftriaxone sodium; ciprofloxacin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients

    NCT00760032

    Registered record
    Registry ID
    NCT00760032
    Conditions
    Cirrhosis; Ascites; Infections
    Interventions
    Ciprofloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Ascites; Infections
    InterventionCiprofloxacin; Placebo
    PhasePhase 4
    Registry statusWithdrawn